RecruitingNot ApplicableNCT07009093
Utility of a Mobile Application for Young Women With Breast Cancer
Sponsor
Wake Forest University Health Sciences
Enrollment
120 participants
Start Date
Apr 1, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
This study aims to evaluate the use of mobile technology as a communication tool among patients with breast cancer and measured its effect on patient-reported cancer-related distress, specifically focusing on young women as they often face unique challenges.
Eligibility
Sex: FEMALEMin Age: 18 YearsMax Age: 45 Years
Inclusion Criteria9
- Ability to understand and willingness to sign an IRB-approved informed consent
- Age ≥ 18 and ≤ 45 years at the time of consent
- Female
- Established patient at Atrium Health Wake Forest Baptist Comprehensive Cancer Center (AHWFBCCC)
- Histological confirmation of any type and stage (0-IV) of breast cancer
- Screening (baseline) NCCN Distress Thermometer score ≥ 4
- Access to a mobile device for trial purposes and an active email address
- Ability to read and understand the English language. NOTE: The Mighty Pro Application is available in English only.
- As determined by the enrolling Investigator, ability of the participant to understand and comply with study procedures for the entire length of the study
Exclusion Criteria1
- \- None
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERMighty Pro Application
Access to Mighty Pro Application
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07009093
Related Trials
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
NCT0720582240 locations
A Study of Language Interpretation Solutions for People With Breast Cancer
NCT067210658 locations
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
NCT03488693485 locations
The T-REX Trial: Tailored Regional External Beam Radiotherapy in Clinically Node-negative Breast Cancer Patients With 1-2 Sentinel Node Macrometastases.
NCT0563488930 locations
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
NCT0722226725 locations